Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Hematological Malignancies
DRUG: AZD9829|DRUG: AZD9829
Frequency of dose limiting toxicities (DLTs)., DLTs are dose-limiting toxicities as defined in the study protocol., Module 1 - 28 days.|Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Frequency, severity and relationship to study drug of AEs and SAEs, Module 1 - From informed consent until 60 days after last dose of AZD9829.|Identify RP2D in R/R AML patients., Incidence of AEs/SAEs and PK data, Moldule 1 -From informed consent until 60 days after last dose of AZD9829.
Pharmacokinetics of AZD9829: Plasma Concentration of total antibody, Measurement of plasma concentration of conjugated and unconjugated antibody, Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Plasma Concentration of total unconjugated warhead, Measurement of plasma concentration of total unconjugated warhead, Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Area under the concentration time curve (AUC)., Area under the plasma concentration-time curve., Module 1 - From date of first dose of AZD9829up until 30 days post last dose.|Pharmacokinetics of AZD9829: Maximum plasma concentration of the study drug (Cmax)., Maximum observed plasma concentration of AZD9829., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Time to maximum concentration (tmax), Time to maximum observed plasma concentration of the study drug., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Clearance, The volume of plasma from which the study drug is completely removed per unit time., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Half-life (t 1/2), Terminal elimination half-life., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Anti-Drug Antibodies (ADA), Evaluating the number of patients who develop anti-drug antibodies (ADA) during treatment., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|Pharmacokinetics of AZD9829: Anti-Drug Antibodies (ADA), Evaluating the percentage of patients who develop anti-drug antibodies (ADA) during treatment., Module 1 - From date of first dose of AZD9829 up until 30 days post last dose.|To determine the immunogenicity of AZD9829., The number of participants who develop ADA (Anti Drug Antibodies)., Module 1 - From first dose to the 30-Day SFU visit|To determine the immunogenicity of AZD9829., The percentage of participants who develop ADA (Anti Drug Antibodies)., Module 1 - From first dose to the 30-Day SFU visit|Overall Response Rate (ORR), Overall response rate disease assessments in accordance with ELN2022 recommendations for AML and IWG 2006/2018 for MDS., Module 1 - From first dose of AZD9829 until disease progression or end of the study (upto approximately 1 year)|Composite Complete Response Rate (CCRR), Composite CR rate disease assessment in accordance with ELN2022 for AML and IWG 2006/2018 for MDS., Module 1 - From first dose of AZD9829 up to approximately 1 year.|Complete remission with incomplete hematologic recovery (CRi), The endpoint of complete remission with CRi as defined by ELN2022 criteria., Module 1 - From first dose of AZD9829 up to approximately 1 year.|Complete Response (CR), Complete response (CR) according to ELN2022 for AML and IWG 2006/2018 for MDS., Module 1 - From first dose of AZD9829 up to approximately 1 year.|Duration of Response (DoR), Time from first documented response until the date of relapse or death., Module 1 -Time from first documented response until disease progression or death (approximately 1 year).|Time to Response (TTR), Time from first dose to the achievement of first overall response. Disease assessments will follow ELN2022 for AML and IWG 2006/2018 for MDS., Module 1 - From first dose of AZD9829 until complete remission, disease progression or death (approximately 1 year).|Time to Next Treatment (TTNT), The time from the start of treatment date until the date of subsequent antileukemia therapy., Module 1 - From first dose of AZD9829 until the date of subsequent anti-leukemia-therapy or death (approximately 1 year).|Progression-free Survival (PFS), The time from the start of treatment date until the date of disease progression or death., Module 1 - From first dose of AZD9829 until disease progression or death (approximately 1 year).|Overall Survival (OS), The time from the start of treatment date until death., Module 1 - From first dose of AZD9829 until death (approximately 1 year).|Event-free Survival (EFS), The time from the start of treatment date to disease progression, death, or initiation of a new anti-leukemic therapy., Module 1 - From first dose of AZD9829 until disease progression, death, or initiation of a new anti-leukemic therapy (approximately 1 year).
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.